Qualigen Therapeutics, Inc. (NASDAQ:AIXC) Short Interest Up 104.6% in June

Qualigen Therapeutics, Inc. (NASDAQ:AIXC) saw a large increase in short interest during the month of June. As of June 30th, there was short interest totaling 162,797 shares, an increase of 104.6% from the June 15th total of 79,560 shares. Based on an average daily trading volume, of 263,099 shares, the days-to-cover ratio is currently 0.6 days. Currently, 0.8% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Qualigen Therapeutics in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Qualigen Therapeutics has a consensus rating of “Sell”.

Qualigen Therapeutics Stock Down 1.1%

NASDAQ:AIXC opened at $0.98 on Thursday. The firm has a market cap of $19.83 million, a price-to-earnings ratio of -0.15 and a beta of 0.49. The firm’s 50 day moving average is $1.24. Qualigen Therapeutics has a 12-month low of $0.90 and a 12-month high of $8.81.

Qualigen Therapeutics (NASDAQ:AIXC) last issued its earnings results on Tuesday, May 12th. The company reported ($0.79) earnings per share for the quarter.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc, a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient’s blood.